



MELIOR DISCOVERY RECEIVES PATENT APPROVAL FROM U.S. PATENT AND TRADEMARK OFFICE FOR NEW PARKINSON'S DISEASE DRUG CANDIDATE

**-Patent to cover repositioned small molecule drug candidate MLR-1019-
- MLR-1019 is expected to treat L-DOPA-induced dyskinesia while improving the
therapeutic effects of L-DOPA-**

June 10, 2015 Exton, PA – Melior Discovery, Inc. announced today that the United States Patent and Trademark Office (USTPO) has awarded a patent to the company for its Parkinson's disease candidate, MLR-1019. The patent covers the use of this therapeutic for treating dyskinesia associated with L-DOPA therapy in Parkinson's disease.

"This recent patent award will provide robust protection for MLR-1019 through 2034, and represents a significant milestone towards Melior's second major development program," said Andrew Reaume PhD, President and CEO of Melior Discovery.

About MLR-1019

MLR-1019 is a repositioned small molecule drug candidate that Melior is developing for treating Parkinson's disease. Extensive animal model data indicates that MLR-1019 will have the unique property of attenuating patients' dyskinesia while simultaneously improving the therapeutic benefit of L-DOPA.

About Melior

Melior Discovery and Melior Pharmaceuticals, its sister company, are leaders in pharmaceutical drug repositioning using the unique *theraTRACE*® platform comprised of multiplexed *in vivo* disease models. Melior is using these capabilities to build an internal pipeline of development candidates and also partners with pharmaceutical and biopharmaceutical companies to apply the *theraTRACE*® platform and its in-depth *in vivo* pharmacology expertise to their development candidates. Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com.

For more information contact:

Andrew Reaume, Ph.D, MBA
President and CEO
Melior Discovery
(+1) 610-280-0633 ext 239

e-mail: areaume@meliordiscovery.com